Cost-effectiveness analysis of the addition of rituximab to CHOP in young patients with good-prognosis diffuse large-B-cell lymphoma

Clinical Drug Investigation

Volumn 28, Issue 1, 2008, Pages 55-65

  Ferrara, Felicetto ^a   Ravasio, Roberto ^b  

^a CARDARELLI HOSPITAL   (Italy)

^b Adis International Ltd   (Italy)

Author keywords

Cost effectiveness; Cyclophosphamide, therapeutic use; Diffuse large B cell lymphoma; Doxorubicin, therapeutic use; Prednisone, therapeutic use; Rituximab, therapeutic use; Vincristine, therapeutic use

Indexed keywords

BETA 2 MICROGLOBULIN; BLEOMYCIN; CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; MELPHALAN; MESNA; METHOTREXATE; PREDNISONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB; VINCRISTINE;

APHERESIS; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BILIRUBIN BLOOD LEVEL; BLOOD CELL COUNT; BONE MARROW BIOPSY; CALCIUM BLOOD LEVEL; CHLORIDE BLOOD LEVEL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; CREATININE BLOOD LEVEL; DIAGNOSTIC IMAGING; DIFFUSE LARGE B CELL LYMPHOMA; DRUG COST; DRUG EFFICACY; ECHOGRAPHY; ELECTROPHORESIS; FOLLOW UP; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HEMATOLOGY; HISTOLOGY; HUMAN; INCIDENCE; LACTATE DEHYDROGENASE BLOOD LEVEL; LYMPHOMA; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; SENSITIVITY ANALYSIS; SODIUM BLOOD LEVEL; THORAX RADIOGRAPHY; UREA BLOOD LEVEL; URIC ACID BLOOD LEVEL;

EID: 37249071776     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200828010-00007     Document Type: Article

References (33)

1. Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994 Sep 1; 84: 1361-92
2. Jaffe ES, Harris NL, Stein H, et al., editors. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. World Health Organization classification of tumours. Lyon: IARC Press, 2001
3. Mounter PJ, Lennard AL. Classic diseases revisited: management of non-Hodgkin's lymphomas. Postgrad Med J 1999; 75: 2-6
4. Vose JM, Chiu BCH, Cheson BD. Update on epidemiology and therapeutics for non-Hodgkin's lymphoma. Hematology Am Soc Hematol Educ Program 2002: 241-62
5. Ries LAG, Eisner MP, Kosary CL, et al. SEER cancer statistics review, 1973-1999. Bethesda (MD): National Cancer Institute, 2002
6. Coiffier B. Non Hodgkin's lymphomas. In: Cavalli F, Hansen HH, Kaye SB, editors. 3rd edition. Textbook of medical oncology. London: Martin Dunitz, 1997: 265-87
7. Ballatori E, Berto P, Roila F. L'analisi farmacoeconomica in oncologia. Roma: Il Pensiero Scientifico Editore, 1999
8. Tilly H, Lepade E, Coiffier B, et al. A randomized comparison of ACVBP and CHOP in the GELA study treatment of advanced aggressive non-Hodgkin's lymphoma: the LNH93-5 study [abstract]. Blood 2000; 96: 832a
9. Sehn LH, Donaldson J, Chhanabhai M. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large b-cell lymphoma in British Columbia. J Clin Oncol 2005; 23: 5027-33
10. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993; 329: 987-94
11. Pfreundschuh M, Trumper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006; 7 (5): 379-91
12. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999; 17: 1244
13. Pocali B, De Simone M, Annunziata M, et al. Ifosfamide, epirubicin and etoposide (IEV) regimen as salvage and mobilization therapy for refractory or early relapsing patients with aggressive non-Hodgkin's lymphoma. Leuk Lymphoma 2004; 45 (8): 1605-9
14. Mey UJ, Orlopp KS, Flieger D, et al. Dexamethasone, high-dose cytarabine, and cisplatin in combination with rituximab as salvage treatment for patients with relapsed or refractory aggressive non-Hodgkin's lymphoma. Cancer Invest 2006 Oct; 24 (6): 593-600
15. . Mey UJ, Olivieri A, Orlopp KS, et al. DHAP in combination with rituximab vs DHAP alone as salvage treatment for patients with relapsed or refractory diffuse large B-cell lymphoma: a matched-pair analysis. Leuk Lymphoma 2006 Dec; 47 (12): 2558-66
16. Sieniawski M, Staak O, Glossmann JP, et al. Rituximab added to an intensified salvage chemotherapy program followed by autologous stem cell transplantation improved the outcome in relapsed and refractory aggressive non-Hodgkin lymphoma. Ann Hematol 2007 Feb; 86 (2): 107-15
17. Mills W, Chopra R, McMillan A, et al. BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin's lymphoma. J Clin Oncol 1995 Mar; 13 (3): 588-95
18. Agenzia Italiana del Farmaco [online]. Available from URL: http://www.agenziafarmaco.it/ [Accessed 2007 May 1]
19. Conferenza delle Regioni e Province Autonome. Tariffa Unica Convenzionale per le prestazioni di assistenza ospedaliera. Regole e tariffe valide per il 2006. 2005 Dec 15, Roma
20. ASSR on line. Confronto tra le aziende ospedaliere 2002. Monitor 2004; 11: 41-59
21. Drummond MF, O'Brien BJ, Stoddart GL, et al. Edizione italiana a cura di Fattore G, Garattini L, Lucioni C. Metodi per la valutazione economica dei programmi sanitari. Rome: Pensiero Scientifico Editore, 2000
22. Jonsson B. Changing health environment: the challenge to demonstrate cost-effectiveness of new compounds. Pharmacoeconomics 2004; 22 Suppl. 4: 5-10
23. Tengs TO, Adams ME, Pliskin JS, et al. Five-hundred life-saving interventions and their cost-effectiveness. Risk Analysis 1995; 15 (3): 369-90
24. Czuczman MS, Grillo-Lopez AJ, White CA, et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 1999 Jan; 17 (1): 268-76
25. Zinzani PL, Tani M, Molinari AL, et al. Ifosfamide, epirubicin and etoposide regimen as salvage and mobilizing therapy for relapsed/refractory lymphoma patients. Haematologica 2002 Aug; 87 (8): 816-21
26. Groot MT, Lugtenburg PJ, Hornberger J, et al. Cost-effectiveness of rituximab (MabThera) in diffuse large B-cell lymphoma in The Netherlands. Eur J Haematol 2005 Mar; 74 (3): 194-202
27. Hornberger JC, Best JH. Cost utility in the United States of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone for the treatment of elderly patients with diffuse large B-cell lymphoma. Cancer 2005 Apr 15; 103 (8): 1644-51
28. Best JH, Hornberger J, Proctor SJ, et al. Cost-effectiveness analysis of rituximab combined with CHOP for treatment of diffuse large B-cell lymphoma. Value Health 2005 Jul-Aug; 8 (4): 462-70
29. Knight C, Hind D, Brewer N, et al. Rituximab (MabThera) for aggressive non-Hodgkin's lymphoma: systematic review and economic evaluation. Health Technol Assess 2004; 8 (37): 1-82
30. Berto P, Morsanutto A, Lopatriello S, et al. Analisi di costo-efficacia di rituximab + CHOP versus CHOP in soggetti affetti da linfoma non-Hodgkin aggressivo. Pharmacoeconomics (Italian Research Articles) 2004; 6 (3): 151-60
31. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma. N Engl J Med 2002; 346: 235-42
32. Coiffier B, Herbrecht R, Tilly H, et al. GELA study comparing CHOP and R-CHOP in elderly patients with DLCL: 3-year median follow-up with an analysis according to co-morbidity factors [abstract no. 2395]. Proc Am Soc Clin Oncol 2003; 22: 596a
33. Coiffier B, Herbrecht R, Morel CH, et al. GELA study comparing CHOP and R-CHOP in elderly patients with DLCL: 3-year median follow-up with an analysis according to co-morbidity factors [abstract no. 0356]. Hematology J 2003; 4 Suppl. 2: 111-2